• Je něco špatně v tomto záznamu ?

Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo

L. Beckert, L. Kostka, E. Kessel, A. Krhac Levacic, H. Kostkova, T. Etrych, U. Lächelt, E. Wagner,

. 2016 ; 105 (-) : 85-96. [pub] 20160525

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013822

We report novel pH-reversibly surface-shielded polyplexes with enhanced gene transfer activity upon systemic administration. A four-arm-structured sequence-defined cationic oligomer KK[HK[(H-Sph-K)3HC]2]2 was designed and synthesized on solid-phase, containing additional lysine residues not only for improved pDNA polyplex stability, but also providing attachment points for subsequent polyplex functionalization with amine-reactive shielding polymers. Herein, the surface of polyplexes was shielded with hydrophilic polymers, monovalent PEG or monovalent and multivalent pHPMA, optionally attached to the polyplex via the acid-labile linker AzMMMan. Overall, surface modification with PEG or pHPMA resulted in a decrease in the zeta potential of polyplexes, consistent with the degree of surface shielding. At pH 6.0, only polyplexes modified via the acid-labile linkage showed an increase in zeta potential, consistent with a "deshielding" in acidic environment, expected as beneficial for endosomal escape. Shielding was more efficient for multivalent pHPMA (20kDa, 30kDa) as compared to monovalent pHPMA (10kDa, 20kDa, 30kDa) or PEG (5kDa). In vitro transfection studies revealed higher gene expression by the polyplexes with the acid-labile shield as compared to their irreversibly shielded counterparts. Intravenous administration of AzMMMan-pHPMA modified polyplexes in an in vivo tumor mouse model mediated enhanced gene expression in the subcutaneous tumor and reduced undesirable expression in the liver.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013822
003      
CZ-PrNML
005      
20170502100805.0
007      
ta
008      
170413s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejpb.2016.05.019 $2 doi
035    __
$a (PubMed)27235729
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Beckert, Linda $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
245    10
$a Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo / $c L. Beckert, L. Kostka, E. Kessel, A. Krhac Levacic, H. Kostkova, T. Etrych, U. Lächelt, E. Wagner,
520    9_
$a We report novel pH-reversibly surface-shielded polyplexes with enhanced gene transfer activity upon systemic administration. A four-arm-structured sequence-defined cationic oligomer KK[HK[(H-Sph-K)3HC]2]2 was designed and synthesized on solid-phase, containing additional lysine residues not only for improved pDNA polyplex stability, but also providing attachment points for subsequent polyplex functionalization with amine-reactive shielding polymers. Herein, the surface of polyplexes was shielded with hydrophilic polymers, monovalent PEG or monovalent and multivalent pHPMA, optionally attached to the polyplex via the acid-labile linker AzMMMan. Overall, surface modification with PEG or pHPMA resulted in a decrease in the zeta potential of polyplexes, consistent with the degree of surface shielding. At pH 6.0, only polyplexes modified via the acid-labile linkage showed an increase in zeta potential, consistent with a "deshielding" in acidic environment, expected as beneficial for endosomal escape. Shielding was more efficient for multivalent pHPMA (20kDa, 30kDa) as compared to monovalent pHPMA (10kDa, 20kDa, 30kDa) or PEG (5kDa). In vitro transfection studies revealed higher gene expression by the polyplexes with the acid-labile shield as compared to their irreversibly shielded counterparts. Intravenous administration of AzMMMan-pHPMA modified polyplexes in an in vivo tumor mouse model mediated enhanced gene expression in the subcutaneous tumor and reduced undesirable expression in the liver.
650    _2
$a amidy $x chemie $7 D000577
650    _2
$a zvířata $7 D000818
650    _2
$a DNA $x chemie $7 D004247
650    12
$a technika přenosu genů $7 D018014
650    _2
$a techniky in vitro $7 D066298
650    _2
$a methakryláty $x chemie $7 D008689
650    _2
$a myši $7 D051379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kostka, Libor $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic. Electronic address: kostka@imc.cas.cz.
700    1_
$a Kessel, Eva $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
700    1_
$a Krhac Levacic, Ana $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
700    1_
$a Kostkova, Hana $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic.
700    1_
$a Etrych, Tomas $u Centre for Biomacromolecular and Bioanalogous Systems, Department of Biomedicinal Polymers, Institute of Macromolecular Chemistry Academy of Sciences CR, v.v.i., Heyrovskeho sq. 2, Prague, Czech Republic.
700    1_
$a Lächelt, Ulrich $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany.
700    1_
$a Wagner, Ernst $u Pharmaceutical Biotechnology, Department of Pharmacy, Butenandtstraße 5-13, Building D, 81377 München, Germany. Electronic address: ernst.wagner@cup.uni-muenchen.de.
773    0_
$w MED00001640 $t European journal of pharmaceutics and biopharmaceutics official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 105, č. - (2016), s. 85-96
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27235729 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170502101132 $b ABA008
999    __
$a ok $b bmc $g 1200287 $s 974600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 105 $c - $d 85-96 $e 20160525 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...